Correction: JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $1100. Action Price target changed to Raises
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott maintains an Overweight rating on Eli Lilly and raises the price target from $1050 to $1100.
September 13, 2024 | 4:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Chris Schott has maintained an Overweight rating on Eli Lilly and increased the price target from $1050 to $1100, indicating confidence in the company's future performance.
The increase in price target from $1050 to $1100 by JP Morgan suggests a positive outlook on Eli Lilly's future performance. Maintaining an Overweight rating indicates continued confidence in the stock, likely leading to a positive short-term impact on its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100